Literature DB >> 34061698

ADHD prevalence in the psychiatric population.

Sina Gerhand1,2, Christopher W N Saville1.   

Abstract

OBJECTIVE: This article presents a systematic literature review of the prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in the adult psychiatric population.
METHODS: Three databases were searched using keywords relating to ADHD and psychiatric disorders. Fifteen studies published before May 2020 met inclusion criteria.
RESULTS: Prevalence rates ranged from 6.9 to 38.75%. There was considerable heterogeneity with regards to the assessment methods of ADHD and comorbidities, the sampling as well as inclusion and exclusion of psychiatric comorbidities. Research concluded that ADHD is underdiagnosed in this population. Gender ratios also varied between 1.8:1 and 1:2.5 (male:female).
CONCLUSIONS: All ADHD prevalence rates for the psychiatric population were considerably higher than the 2.8% estimated for the general adult population. ADHD should be kept in mind for psychiatric patients to ensure accurate diagnosis and optimal treatment options.Key PointsADHD is considerably underdiagnosed in the psychiatric populationGender ratios between 1.8:1 and 1:2.5 (male:female) reported in researchMore research is needed to ascertain if the use of ADHD screening instruments would improve the recognition and treatment of adult ADHD in the psychiatric population.

Entities:  

Keywords:  ADHD; attention deficit hyperactivity disorder; comorbidity; hyperkinetic disorder; prevalence; psychiatric disorders

Mesh:

Year:  2021        PMID: 34061698     DOI: 10.1080/13651501.2021.1914663

Source DB:  PubMed          Journal:  Int J Psychiatry Clin Pract        ISSN: 1365-1501            Impact factor:   2.750


  1 in total

Review 1.  The lived experiences of adults with attention-deficit/hyperactivity disorder: A rapid review of qualitative evidence.

Authors:  Callie M Ginapp; Grace Macdonald-Gagnon; Gustavo A Angarita; Krysten W Bold; Marc N Potenza
Journal:  Front Psychiatry       Date:  2022-08-11       Impact factor: 5.435

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.